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Abstract 
Covalently-modified blood proteins (e.g., serum albumin adducts) are increasingly being viewed as 
potential biomarkers via which the environmental causes of human diseases may be understood. The 
notion that some (perhaps many) modifications have yet to be discovered has led to the development 
of untargeted adductomics methods, which attempt to capture entire populations of adducts. One such 
method is fixed-step selected reaction monitoring (FS-SRM), which analyses distributions of serum 
albumin adducts via shifts in the mass of a tryptic peptide [Li et al. (2011) Mol. Cell. Proteomics 10, 
M110 004606]. Working on the basis that FS-SRM might be able to detect biological variation due to 
environmental factors, we aimed to scale the methodology for use in an epidemiological setting. 
Development of sample preparation methods led to a batch workflow with increased throughput and 
provision for quality control. Challenges posed by technical and biological variation were addressed 
in the processing and interpretation of the data. A pilot study of 20 smokers and 20 never-smokers 
provided evidence of an effect of smoking on levels of putative serum albumin adducts. Differences 
between smokers and never-smokers were most apparent in putative adducts with net gains in mass 
between 105 Da and 114 Da (relative to unmodified albumin). The findings suggest that our 
implementation of FS-SRM could be useful for studying other environmental factors with relevance 
to human health. 
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Introduction 
Non-enzymatic covalent modifications to macromolecules represent a source of potential biomarkers 
with which to study human health and disease.
1-4
 In some cases, modifications might be causally 
related to biological endpoints (e.g., a mutagenic lesion in DNA causing cancer
5
). Alternatively, 
modifications might be found in “off-pathway” products from which “on-pathway” events may be 
inferred. This latter possibility has motivated researchers to investigate adducts of blood proteins as 
potential biomarkers, particularly in studies seeking to understand the effects of environmental factors 
on human populations (biomonitoring, exposome studies). The rationale for this approach is that 
exogenous chemicals, or their derivatives, should tend to react with nucleophilic amino acid residues 
in the proteins.
6,7
 Some exogenous chemicals possess intrinsic reactivity towards proteins (e.g., sulfur 
mustard
8
), whilst others require metabolic activation (e.g., aflatoxins
2
). Less direct mechanisms, in 
which the origin of the reactive chemical is endogenous rather than exogenous, may also occur.
9
 
Haemoglobin and human serum albumin (HSA) are two blood proteins that have been used 
extensively for biomonitoring.
10-12
 HSA, for example, is ideally suited for this purpose on account of 
its reactivity (at Cys-34 and other nucleophilic loci
13
), abundance (approx. 40 g L
−1
 in serum
14
) and 
long physiological half-life (approx. three weeks
15
). Some adducts of blood proteins have been known 
for decades, and targeted methods for their detection have been established.
2
 It is only recently, 
however, that “-ome” concepts have been applied to DNA and protein adducts, and that 
corresponding “-omics” methods have been applied to their detection.1,6,11,16 The idea that known 
adducts might exist within a wider adductome has led to the development of untargeted adductomics 
methods for the discovery of novel biomarkers. In 2011, Li et al. reported the use of fixed-step 
selected reaction monitoring (FS-SRM), a triple quadrupole mass spectrometry (TQ-MS) method for 
HSA adductomics.
17
 The authors detected modifications within a short sequence of amino acid 
residues in HSA (residues 27-41) via shifts in a sequence tag
18
 of the third-heaviest tryptic peptide 
(“T3”). Such a shift may be characterised by the mass of a putative “R” group17 (presumably attached 
to the sulfur atom of Cys-34) or, as below, by the net gain in molecular mass due to the modification 
(d).  
Detection by TQ-MS involves the use of quadrupole mass analysers to exclude all but the ions of 
interest. Under appropriate conditions, a precursor ion gains a stable trajectory in the first quadrupole 
(Q1), and its product does likewise in the third quadrupole (Q3). If, for T3 peptides of HSA adducts, 
the product ions are always related to their precursors by a constant loss of mass (i.e., a loss that is 
independent of d), then the loss may be used as a basis on which to detect unknown adducts (Fig. 1A). 
Thus, for untargeted adductomics, the conditions in Q3 are offset relative to those in Q1 according to 
the constant loss, and the respective conditions are co-varied as a function of d (Fig. 1B). In FS-SRM, 
this co-varying of conditions is done in a step-wise fashion (pseudo constant neutral loss scanning
1,16
). 
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By devoting more time to fewer measurements (cf. conventional scanning), stepped methods should 
benefit from enhanced sensitivity, accuracy and precision. These benefits are gained at the expense of 
resolution, meaning that the usefulness of FS-SRM comes not from an ability to identify particular 
adducts, but rather from the characterisation of their distribution as a whole. If the closeness of the 
step-wise measurements is balanced with the range of masses transmitted by Q1, then the method 
should detect any and all relevant HSA adducts. Li et al.
17
 refer to the range of masses captured by a 
single measurement as a bin (Fig. 1B). We refer to the values of d at which measurements are made as 
sampling points (SPs), and we use the variable dSP to distinguish them from the d-values of adducts 
(dadduct). Each SP can be described in terms of the m/z values of a precursor ion and one or more 
product ions (Fig. 1B). 
Li et al.
17
 applied their methods (sample preparation and FS-SRM; Fig. 2) to analyses of archived 
plasma protein that had been pooled according to subjects’ ethnicities and tobacco smoking habits. 
Differences observed between pools suggested that FS-SRM might be able to detect statistically 
significant differences between groups of individual samples that had not been pooled. On this basis, 
we wished to use FS-SRM in an epidemiological setting
19
, which would necessitate the analysis of 
tens to hundreds of samples per group. In implementing FS-SRM for this purpose, the existing 
methods had to be modified in order to achieve an acceptable throughput of samples. Novel 
adaptations (e.g., use of solid-phase extraction for sample clean-up) enabled faster sample 
preparation. Focusing on a narrower range of SPs enabled the throughput of TQ-MS to be increased. 
Further adaptations (e.g., quality control) were introduced to address challenges associated with 
technical variation, which are a particular concern when the number of samples is large. Methods 
were evaluated first using synthetic and semi-synthetic standards (adducts of maleimides), and then 
by testing for effects of a model environmental factor (tobacco smoking) on the levels of putative 
adducts detected in human plasma (20 smokers and 20 never-smokers from the ENVIRONAGE 
cohort
20
). To our knowledge, this is the first example of FS-SRM being used to investigate 
associations between environmental factors and levels of putative HSA adducts in a quantitative 
fashion. 
Experimental Procedures 
Chemicals 
Synthetic peptides (T3, ALVLIAFAQYLQQCPFEDHVK; and isotopically-labelled T3, AL[valine-
13
C5, 
15
N]LIAFAQYLQQCPFEDH[valine-
13
C5, 
15
N]K) were purchased from Insight Biotechnology 
(Wembley, UK). N-(Naphthalen-1-yl)maleimide was purchased from Santa Cruz Biotechnology 
(Heidelberg, Germany). Bovine serum albumin, 5,5ʹ-dithiobis(2-nitrobenzoic acid) (Ellman’s 
reagent), N-ethylmaleimide (NEM), GSH, human serum from male AB plasma, HSA, lyophilised 
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citrated bovine plasma, lyophilised citrated human plasma, propranolol hydrochloride and porcine 
trypsin (unmodified) were purchased from Sigma-Aldrich (Dorset, UK). Solvents (HPLC-grade and 
LC-MS-grade) and other general laboratory chemicals were purchased from Alfa Aesar (Lancashire, 
UK), Fisher Scientific (Loughborough, UK), Oxoid (Hampshire, UK), Sigma-Aldrich or VWR 
International (Leicestershire, UK). All commercial substances were used without further preparation 
except for LC-MS-grade solvents (de-gassed by water-bath sonication) and lyophilised plasma 
(reconstituted with water). Water for general purposes (18.2 MΩ cm) was obtained using an ELGA 
purification apparatus (Veolia Water Technologies, High Wycombe, UK). 
Preparation of Standards 
An isotopically-labelled internal standard (S-carbamidomethylated isotopically-labelled T3, “Cam-
iT3”) was prepared as described previously.21 Similar methods were used to prepare a N-(naphthalen-
1-yl)succinimid-3-yl derivative of T3 (Nns-T3) as a mixture of putative isomers. Details can be found 
in the Supporting Information (SI). Both synthetic peptide adducts were obtained as eluates from 
reversed-phase HPLC. Cam-iT3 was quantified using analytical HPLC with fluorescence detection as 
described in the earlier report.
21
 NEM-modified HSA (Nes-HSA; expected modification: S-[N-
ethylsuccinimid-3-yl]), for use in the preparation of Nes
+
 plasma (i.e., “control plasma” containing 
Nes-HSA; see below), was prepared by reacting partially-reduced commercial HSA with NEM in 
PBS (see SI). Nes
+
 plasma was prepared by adding a solution of Nes-HSA (1.4 mg) in PBS (50 µL) to 
commercial human plasma (5 mL). Nes
−
 plasma (i.e., control plasma lacking Nes-HSA) was prepared 
in the same way, except that unmodified commercial HSA was added in place of Nes-HSA. Plasma 
preparations were stored as 50-µL aliquots at −80 °C. 
Summary of Sample Preparation Methods 
HSA was prepared from plasma using a method similar to that of Li et al.
17
, but with the difference 
that adducts were not enriched (see SI for full details). Briefly, most of the unwanted plasma protein 
was salted out with ammonium sulfate, and low-molecular-weight solutes were exchanged with Tris-
HCl buffer (50 mM, pH 8.0). The resulting HSA-rich extract had a final volume of 550 µL (fresh 
plasma) or 450 µL (control plasma; smaller volume due to lower protein content), and contained 
protein recovered from the equivalent of 18 µL of plasma. An aliquot of each extract, containing 
protein from the equivalent of 2.68 µL of fresh plasma or 3.28 µL of control plasma, was subjected to 
further processing. The conditions used for protein denaturation (TCEP hydrochloride, methanol, 
heat) and digestion (trypsin, pressure cycling, heat) were similar to those described by Li et al., but 
samples were processed in batches rather than individually. The digestion mixture was scaled down to 
fit into a smaller tube (PCT MicroTube; Pressure Biosciences, MA, USA). Up to twelve tubes could 
be accommodated in the pressure cycling instrument (Barocycler NEP2320; Pressure 
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Biosciences/Constant Systems, Northants, UK). Digestion products were prepared for FS-SRM in one 
of two ways: by analytical-scale preparative HPLC (ASP-HPLC; see SI), or by solid-phase extraction 
(SPE; see below). This “decoupled” approach (clean-up followed by offline TQ-MS) is preferred over 
conventional hyphenated analysis because FS-SRM takes longer than the width of a typical 
chromatographic peak.
17
 In the present study, ASP-HPLC was used initially during method 
development, with SPE being introduced later to increase the throughput of sample clean-up. For 
comparison, both methods were used to fractionate a “mock digest” containing Cam-iT3, Nns-T3 and 
the usual buffers and additives. Relevant eluates were analysed using electrospray ionisation ion trap 
mass spectrometry (see SI).  
Solid-Phase Extraction 
Digestion products were separated using reversed-phase SPE on a polymeric sorbent (Strata-X, 30 
mg/1-mL tube; Phenomenex, Macclesfield, UK). SPE tubes were attached to a ten-port vacuum 
manifold (Biotage, Uppsala, Sweden), and conditioning/loading/washing/elution was achieved by 
drawing solutions through the sorbent under house vacuum. The sorbent was conditioned with a 
solution of 0.1% (v/v) formic acid in acetonitrile (1 mL), then equilibrated with a solution of 0.1% 
(v/v) formic acid in 17:3 (v:v) water:acetonitrile (2 × 1 mL). The reservoir of the SPE tube was 
charged with a 0.1% (v/v) solution of formic acid in 37:1 (v:v) water:acetonitrile (600 µL), and 
digestion products were added from the PCT MicroTube (see above). The MicroTube was washed 
with a 1% (v/v) solution of formic acid in 1:1 (v:v) water:acetonitrile (145 µL), and the washings were 
added to the SPE tube. Cam-iT3 (90 pmol) was added, and the tube was sealed with a 
poly(tetrafluoroethylene) cap (Supelco; Sigma-Aldrich, Dorset, UK). The contents of the reservoir 
(pH ~ 3) were mixed by inverting the tube once. The cap was removed, and the digestion products 
and Cam-iT3 were loaded onto the sorbent. The sorbent was then washed with a 0.1% (v/v) solution 
of formic acid in 4:1 (v:v) water:acetonitrile (5 × 1 mL). Peptides of interest were eluted with a 0.1% 
(v/v) solution of formic acid in 1:3 (v:v) water:acetonitrile (2 × 500 µL) into a 2-mL polypropylene 
microcentrifuge tube (Eppendorf, Stevenage, UK). The eluate was vortexed-mixed to homogeneity 
and centrifuged (16,000 × g, 2 min). Supernatant (300 µL) was transferred to a centrifugal filter unit 
(Costar Spin-X, nylon, pore size = 0.22 µm; Corning, New York, USA) that had been pre-rinsed with 
eluent, and the unit was centrifuged (10,000 × g, 1 min). Filtrate (250 µL) was transferred to a glass 
autosampler vial with a 300-µL fused insert (Fisher Scientific, Loughborough, UK). 
FS-SRM 
FS-SRM was performed using a Thermo TSQ Quantum Access triple quadrupole mass spectrometer 
(Thermo Fisher Scientific, Hemel Hempstead, UK) operated in SRM mode. Three major 
modifications were made to the method of Li et al. (see SI for the full method). Firstly, the chip-based 
system used for sample delivery was replaced with a Dionex Ultimate 3000 liquid chromatograph and 
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a Nanospray Flex ion source (both from Thermo Fisher Scientific). Secondly, only 32 of the 77 SPs 
were used (71.1 Da ≤ dSP ≤ 210.6 Da). The other SPs were omitted as a compromise between mass-
range coverage and analytical throughput. The chosen SPs represent a continuous range that is 
uninterrupted by potential artefacts (e.g., alkali metal ion adducts), and in which some signals of 
interest had been observed by Li et al.
17
 Additionally, truncation of the range allowed measurements 
to be scheduled in a more consistent fashion (see Table S1). Thirdly, different conditions were used to 
filter product ions in Q3 (see SI), resulting in fewer repeat measurements per 30-second “segment” of 
the analysis. As in the earlier method, putative adducts were detected via a sequence tag consisting of 
a triply-charged precursor ion and three doubly-charged y-ions (y15, y16 and y17; standard peptide 
fragment nomenclature, see SI). Starting from 32 evenly-spaced values of precursor m/z (836 to 
882.5), corresponding values of product m/z were derived using eq 1 (x = 4, 5, 6), and corresponding 
values of dSP were derived using eq 2. The use of molecular weight (Mr) accounts for the apparent 
averaging of m/z that occurs when multiply-charged ions are analysed at low resolution. The step size, 
ΔdSP, was always 4.5 Da (equivalent to 1.5 m/z units of precursor space), except in an evaluation 
experiment where it was reduced to 0.9 Da (0.3 m/z units of precursor space). Sample delivery was 
monitored via targeted detection of the Cam-iT3 internal standard (~20 measurements per segment; 
see Fig. S1 and Table S1).  
Product m/z =   
(Precursor m/z) × 3 - (Mr of bx)
2
 
(1) 
 
dSP= (Precursor m/z) × 3 - (Mr of [T3 + 3H]
3+) 
(2) 
 
Pilot Study of Tobacco Smoke Exposure 
The study included 40 mothers from the ENVIRonmental influence ON AGEing in early life 
(ENVIRONAGE) birth cohort in Belgium. Questionnaires provided information on age, education, 
smoking status, ethnicity and pre-pregnancy body mass index (Table 1). All procedures were 
approved by the Ethical Committee of Hasselt University and East-Limburg Hospital. The study 
design and procedures were described in detail previously.
20
 Briefly, written informed consent was 
obtained from each participating mother who gave birth in the East-Limburg Hospital in Genk, 
Belgium. Twenty mothers who reported smoking during pregnancy and 20 mothers that had never 
smoked were selected based on their self-reported smoking behaviour. For smokers the median 
number of cigarettes per day during pregnancy was 7.25 (maximum: 40; minimum: 1; interquartile 
range: 4.88-10.00; see Table S4) and the median number of pack-years was six (interquartile range: 
4.50-9.31). Peripheral blood was collected one day after parturition in Vacutainer® plastic whole 
blood tubes with spray-coated K2EDTA (BD, Franklin Lakes, NJ, USA). Within 20 min of blood 
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collection, samples were centrifuged (3,200 rpm, 15 min) to isolate plasma. Plasma was collected and 
stored in microcentrifuge tubes (Eppendorf) at −80 °C. To assess the reliability of self-reported 
tobacco consumption, plasma cotinine concentrations (Table S4) were measured using an enzyme-
linked immunosorbent assay kit (product ref. CO096D; Calbiotech, Spring Valley, CA, USA). 
Smoking status was inferred using a cut-off value of 14 ng mL
−1
 (typical literature cut-off for serum 
cotinine concentrations
22
). 
Each smoker’s sample was paired with one from a never-smoker based on the storage time of the 
plasma. Twenty pairs were distributed randomly among five batches. For ten randomly-selected pairs, 
the default order of analysis (never-smoker then smoker) was reversed. To assess among-batch 
variation, an aliquot of Nes
+
 plasma (positive control) was analysed at the end of every batch. 
Analysts were blinded to the identities of the subjects’ samples during sample preparation and TQ-
MS. The five batches of subjects’ samples were processed consecutively. To assess within-batch 
variation, a sixth batch consisting of nine aliquots of Nes
+
 plasma was also included.  All 54 analyses 
were then replicated using different aliquots of the same plasma samples. For the second round of 
analyses, the only change was in the order of the batches (i.e., the order of samples within batches was 
the same). The complete schedule of analyses is depicted in Fig. S3.  
Quantity and Quality of Extracted Protein 
The concentration of protein in each plasma extract was determined using the bicinchoninic acid 
(BCA) assay (Pierce/Thermo Fisher Scientific, Paisley, UK; manufacturer’s protocol with minor 
modifications). Undiluted extracts (15 µL) were analysed in triplicate on 96-well microplates (Greiner 
Bio One, Gloucester, UK), and each plate also included standards (commercial HSA in Tris-HCl 
buffer; five concentrations in duplicate) and quality controls (pooled extracts of Nes
+
 plasma). The 
experimental design described above was transferred to the microplate format, so that extracts in the 
same batch, or from different aliquots of the same plasma, were always analysed on the same 
microplate. BCA working reagent (185 µL) was added to each well, and the microplate was incubated 
at 37 °C for 30 min. After 10 min at ambient temperature, a microplate spectrophotometer (Biotek 
Instruments, Bedfordshire, UK) was used to measure the absorbances (λ = 595 nm). A calibration 
curve was established from the standards’ concentrations and mean absorbances (linear regression 
analysis), and was used to estimate the concentration of protein in each extract. The absolute mass of 
protein in each extract was calculated by multiplying the estimated concentration by the volume. The 
quality of the protein was inferred from a set of three example extracts (one each of smoker’s plasma, 
never-smoker’s plasma and Nes+ plasma), which were analysed using SDS-PAGE (see SI). 
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Processing of FS-SRM Data 
Initial processing of raw data was done using the methods of Li et al. with minor modifications. 
MATLAB code (see Acknowledgements) was used to calculate the apparent amounts of adducts in 
each eluate, and to exclude any result coming from a missing or incomplete sequence tag (MATLAB, 
version 8.2.0.701, The MathWorks, Natick, MA, USA; see SI). The additional validation step 
described by Li et al. was used for a parallel analysis of aggregated data (see Results and Discussion), 
but not to exclude any individual data from statistical testing. Partially validated data were processed 
further in R (version 3.2.4; base package).
23
 To account for variation due to different concentrations of 
HSA in the plasma extracts, adduct amounts were normalised using results from the BCA assay (see 
SI). Null responses (missing or incomplete sequence tags) were imputed using random estimates of 
baseline noise (see SI). Stability of the MS conditions was inferred from SRM of the internal standard 
(first measurement of every cycle; see Table S1). Unstable segments were identified by comparing 
stability metrics (segment-wise means and coefficients of variation) to threshold values (Table S5). 
Any data acquired in unstable segments were excluded at this stage (exclusion rate for 
ENVIRONAGE data: 4.3%). Best estimates of response variables for the ENVIRONAGE samples 
were derived from pairs of full technical replicates by averaging if possible. If a result was missing or 
appeared to be a false negative (null response with non-zero counterpart), its counterpart was taken as 
the best estimate. This was done using an R script based on Table S6, and the resulting table of best 
estimates was the primary data set used for statistical testing. 
Statistical Methods 
All statistical tests were carried out using R (version 3.2.4).
23
 The significance level was p = 0.05 
unless stated otherwise. The dependence of responses on concentration variables was assessed using 
linear regression analysis. A two-tailed independent samples t-test was used to test the hypothesis that 
the smokers and never-smokers differed in the masses of protein recovered from their plasma. The 
Pearson correlation coefficient (r) was used to compare masses of protein recovered in technical 
replicates. The similarity between pairs of adduct distributions from FS-SRM (spectral similarity
24
; 
one coefficient per pair, 32 SPs per comparison) was quantified as the Spearman rank correlation 
coefficient (ρ). Spearman’s ρ was also used to test for agreement between technical replicates (one 
coefficient per SP, ≤40 subjects per comparison). The Wilcoxon rank-sum test (one test per SP, 40 
subjects per comparison) was used to test for associations between smoking status and levels of 
putative HSA adducts. Principal component analysis was used to assess the degree of correlation 
among the 32 sets of responses. Five principal components explained 99% of the variation in the data 
set. To account for making multiple comparisons whilst also taking the degree of correlation into 
consideration
25
, a corrected significance level of p = 0.05/5 = 0.01 was used.  
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Results and Discussion 
Method Development 
In the present study, we adapted the FS-SRM workflow described previously by Li et al.
17
 (Fig. 2). 
For the steps leading to tryptic digestion of HSA, our only major modification was to omit the adduct 
enrichment procedure (removal of mercapto-HSA using covalent chromatography). In an earlier 
study, Funk et al.
26
 showed that such a procedure can facilitate high-level adduct enrichment, but 
noted that better results were obtained when the protein starting material had been isolated from 
freshly-collected plasma. When we attempted enrichment of a model adduct spiked into commercial 
serum (method similar to the one described by Li et al.
17
; see SI), only a modest proportion of the 
albumin was removed (mean ± s.d. = 39.5 ± 1.2%; four replicates). Being more similar to Funk and 
co-workers’ results for archived plasma protein, this result pointed to a sample-dependent effect that 
would have been difficult to control for in the present study. A secondary consideration was the 
throughput of sample preparation, which was enhanced by omitting the enrichment procedure (see 
SI).  
SDS-PAGE of three example extracts (see Supplementary Methods and Fig. S7) indicated that HSA 
was always the major component, and that the ratio of HSA to the major impurity (probably 
transferrin
14
) did not vary appreciably. From these results, we inferred uniformity of relative HSA 
concentration (fraction, w/w, of total protein) across all samples. This inference was supported by 
evidence from the literature.
27
 In an extract consisting of only HSA and transferrin, for example, the 
relative HSA concentration should vary only between 92% and 96% (assumption: no respective 
enrichment of either protein). We considered whether it was necessary to quantify the extracted 
protein prior to digestion. Quantification is advantageous because it allows variation in the protein 
concentration (physiological and/or technical in origin) to be corrected for by dilution. Such 
corrections allow the amount of an adduct to be calculated as a fraction (w/w) of total protein. An 
alternative approach would be to dilute all extracts to the same fixed volume and allow the protein 
concentration to vary freely. Different amounts of protein would be digested, and the results of FS-
SRM would relate to absolute concentrations instead of fractions of total protein. In the present work, 
we explored both possibilities: the volume was fixed and the protein concentration was measured but 
not adjusted (see below). Results for standards and quality controls indicated that the BCA assay used 
to measure protein content was accurate, precise and stable (Fig. S8 and Table S10). 
For tryptic digestion, the method of Li et al.
17
 was adapted so that samples could be processed in 
parallel rather than individually. For clean-up of the digestion products, an ASP-HPLC method was 
implemented initially
17,28
, but was later replaced by SPE (parallel clean-up of up to ten samples, no 
possibility of carry-over, and throughput at least twice that of ASP-HPLC). To ensure that the range 
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of adducts purified by SPE was at least as wide as that of ASP-HPLC, a comparison was made using 
two standards (Cam-iT3 and Nns-T3). Mass spectrometric analyses indicated that both methods could 
elute Cam-iT3 and Nns-T3 completely in a single, appropriately-sized volume of eluate (Fig. S9). 
Evaluation of FS-SRM 
The capabilities of FS-SRM were explored using Nes
+
 controls, which were mixtures of normal 
human material (plasma or serum) and NEM-treated HSA (Nes-HSA). FS-SRM of Nes
+
 plasma 
produced a distinctive distribution of responses (Fig. 3A). The response at one of the SPs (d_125.1) 
was consistent with the presence of NEM-modified Cys-34 (calculated d = 125 Da). The other 
responses were attributed tentatively to components of normal plasma. Analysis of Nes
−
 plasma (no 
NEM treatment) confirmed that Nes-HSA was responsible for the majority of the response at d_125.1, 
but not for any of the other prominent responses (Fig. 3B). Analysis of bovine plasma confirmed that 
none of the prominent responses were due to methods, reagents or some general property of plasma 
(Fig. 3C). Since Nes-HSA is a special case (dadduct = dSP), cases where dadduct was offset relative to dSP 
were also investigated. To do this, a Nes
+
 serum extract was analysed using SPs that were closer 
together (ΔdSP = 0.9 Da). From the results (Fig. 4), it was possible to simulate the effect of varying 
dadduct on the response at dSP. This confirmed that ΔdSP = 4.5 Da was an appropriate spacing, but it also 
revealed that the magnitude of the response declined as the offset increased. The results in Fig. 4 also 
highlight how different adducts with similar masses could potentially be detected at the same SP. The 
responsiveness of FS-SRM was investigated further by varying absolute and relative amounts of Nes-
HSA. Dilution series were prepared from an extract of Nes
+
 serum (diluent: buffer or solution of Nes
−
 
protein) and FS-SRM was performed as usual. In one experiment, the relative amount of Nes-HSA 
was fixed at 1.0% (w/w) and the amount of total protein was varied. The dependence of the d_125.1 
response on the amount of total protein was positive and linear (Fig. 5A), and a similar trend was 
observed at some of the other SPs (Fig. S10). The observed proportionality became important when 
investigating human population samples in which the amount of protein was subject to biological 
variation (see below).  In a different experiment, the amount of total protein was fixed and the relative 
amount of Nes-HSA was varied. The dependence of the d_125.1 response on the relative amount of 
Nes-HSA showed clear evidence of linearity above ~0.2% (w/w), but below this the responsiveness 
appeared dampened (Fig. 5B). Nevertheless, Nes-HSA was frequently still detectable in relative 
amounts as low as 0.04% (w/w) and, if suspected false negatives were discounted, the response was 
still positively associated with the relative amount of Nes-HSA. The trend observed in Fig. 5B for 
d_125.1 was not apparent at any other SPs because the concentration of total HSA (and therefore of 
other adducts) was constant (Fig. S11).  
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Throughput Analysis 
Method development reduced the time required for sample preparation from 85 min to 22 min 
(average time per sample excluding protein quantification). Omitting the adduct enrichment step also 
eliminated an overnight incubation. Reducing the number of SPs from 77 to 32 increased the 
throughput of TQ-MS by an estimated 44%. 
Pilot Study of Tobacco Smoke Exposure 
Results for the ENVIRONAGE subjects revealed substantial variation in the recovery of protein 
(mean ± s.d. = 611 ± 138 µg). Amounts of protein recovered from different aliquots of the same 
plasma were, however, well-correlated (r = 0.90, p = 7.53 × 10
−15
; Fig. S12), suggesting that much of 
the observed variation was biological rather than technical. The amount of protein recovered from 
self-reported smokers (mean ± s.d. = 667 ± 135 µg) was higher than that from never-smokers (mean ± 
s.d. = 554 ± 120 µg) and the difference was statistically significant (p = 0.00794). In other 
populations, investigators have observed either the opposite relationship
29
 or no significant 
difference.
30
 One possible explanation for our observations would be a modulation of the effect of 
smoking by pregnancy, although the findings of other recent work are generally inconsistent with this 
idea.
31
 To simplify interpretation of the FS-SRM results, it was decided that statistical analyses should 
focus on variation that could not be formally explained by differences in protein concentration. Thus, 
an attempt was made to correct for these differences using simple normalisation (eq S1), for which the 
compositional analysis (see above) and the result in Fig. 5A provided some justification. Normalised 
responses were found to be distributed among the SPs in a reproducible fashion (e.g., response at 
d_107.1 tending to be among the highest, response at d_93.6 tending to be among the lowest). 
Reproducibility in this respect was quantified by comparing the distribution of median responses for a 
set of plasma aliquots with that for an identical second set. The results indicated that the shapes of the 
distributions were reproducible, irrespective of smoking status (spectral similarity for never-smokers: 
ρ = 0.84, p = 4.29 × 10−7; for smokers: ρ = 0.85, p = 3.19 × 10−7). Among the responses measured at a 
given SP there was substantial technical variation, and it was likely that many responses lay outside of 
their respective linear dynamic ranges. False negatives were relatively common (e.g., no response 
detected at d_111.6 in 16% of controls), so steps were taken to minimise their influence on the results 
of statistical testing (see Experimental Procedures). The occurrence of false negatives partly explains 
why responses for different aliquots of the same plasma were often not correlated. Notably, however, 
a correlation was observed for responses at d_107.1 (ρ = 0.56, p = 2.62 × 10−4). Results from controls 
indicated that TQ-MS was a major source of technical variation (Fig. 6 and Table 2). Also apparent 
was an effect of the order of analysis on the magnitude of the response, although randomisation 
should have mitigated any potential bias conferred by this effect. 
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The similarity between smokers’ and never-smokers’ distributions (spectral similarity, method as 
above: ρ = 0.94, p < 2.2 × 10−16) suggested that at least some of the same putative adducts were 
present in both groups. We tested for associations between responses at SPs and smoking status and 
found that the response at one SP (d_111.6) was significantly positively associated with smoking (p ≤ 
0.000836; Fig. 7 and Table S11). Significance was observed irrespective of the method by which 
smoking status was determined, but only when technical replicates were aggregated to exclude 
suspected false negatives (see Experimental Procedures). The response at another SP (d_170.1) was 
significantly negatively associated with smoking (p = 0.00513) when self-reported smoking statuses 
were used, but the association was only nominally significant when the classification was based on 
plasma cotinine concentration (p = 0.0365). A third SP (d_107.1) was notable because of a nominally-
significant positive association of the response with smoking (p = 0.0132, self-reported smoking 
statuses), and because of the agreement between non-aggregated technical replicates (see above).  
The data set used for the above tests consisted of partially-validated responses (detection of complete 
sequence tags) and imputed null responses (missing or incomplete sequence tags). An assessment of 
specificity was made by comparing partially- and fully-validated data sets. Full validation entailed 
quantitative analysis of the sequence tags, and provided additional evidence that the responses were 
due to T3 peptides. For many of the SPs, partially-validated responses were frequently retained in the 
fully-validated data set. For d_107.1 and d_111.6, the frequencies were 68% and 84%, respectively. A 
notable exception was d_129.6, for which the frequency was only 3%. This low frequency suggested 
that the dominant substance(s) detected at d_129.6 were not T3 peptides.  
In terms of magnitude, our responses were clustered at the lower end of the range reported by Li et 
al.
17
 The apparent amounts of putative adducts (fractions, mol/mol, of total protein) were between ~5 
parts per million and ~0.1% in the present study (note, however, that the apparent amount was about 
one tenth of the actual amount; see Fig. 5B) and between ~5 parts per million and ~5% in the earlier 
study. In both studies there were notable responses at d_72.1 and d_156.6 (our nomenclature). Li et 
al.
17
 observed their highest responses at d_80.1, whereas we observed low responses at this SP; and 
the opposite was true of the responses at d_107.1. The origins of these inconsistencies (presumably 
subtle differences in samples and/or methods) remain unclear. We also found it instructive to consider 
the results of others’ recent analyses using alternative methods.32-34 Assuming no effects of 
differences in sample preparation or analytical conditions (exception: use of reducing agents 
precluding detection of S-thiolation), eight of the features detected by alternative methods would, if 
present, be detectable using FS-SRM. Notably, responses at d_107.1 are consistent with feature A25 
observed by Grigoryan et al.
33
 (d equivalent to C7H6O) and/or an unidentified feature detected by 
Chung et al.
32
 Responses at d_156.1 are consistent with a putative tryptic transpeptidation product 
suggested by Chung et al.
32  
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Whatever their specific mechanisms of formation, the putative adducts we observed must presumably 
have derived from reactive small molecules in the blood, or been formed somehow during sample 
preparation. Reactive small molecules, or their precursors, may enter the blood from a variety of 
sources (pollution, drugs, endogenous sources, diet). The detection limit of our method corresponds to 
a low-µM concentration of adduct in plasma, which is similar to reported plasma concentrations of 
drugs, endogenous chemicals and dietary chemicals, and is much greater than the plasma 
concentrations of most pollutants.
35
 On this basis, a pollutant-derived adduct would not be detected by 
our method unless the adduct could accumulate to a level much higher than that of the pollutant. The 
naphthoquinone adducts reported by Lin et al.
36
, for example, would be need to be enriched 
approximately 10
3
- or 10
4
-fold to be detectable. On the other hand, Waidyanatha et al.
37
 detected 1,4-
benzoquinone adducts at a level that, providing dadduct was close to dSP, could potentially be detected 
by our method (although enrichment would be required in order to quantify the adduct reliably). The 
above inferences suggest that the putative adducts we observed are less likely to be of pollutants than 
of chemicals from the other sources, but further characterisation will be needed to confirm their 
origins.    
Conclusions 
The FS-SRM methodology for analysing distributions of HSA adducts was adapted for increased 
throughput. Technical aspects of the workflow were evaluated, and its ability to detect biological 
variation in samples of human plasma was explored. The mass coverage (69 Da ≤ d ≤ 213 Da) 
appeared to be essentially uninterrupted and therefore suitable for untargeted analysis. 
Responsiveness was non-uniform with respect to d, but this did not preclude comparisons between 
data sets. Accuracy and precision were best when the amount of adduct was greater than 0.2% (w/w) 
of the total HSA, and when dadduct was close to dSP. Levels of unknowns were often lower than 0.2% 
(w/w), and the high technical variation encountered at these levels (scatter, false negatives) had a 
negative effect on reproducibility. This was addressable to an extent using novel data processing 
methods to aggregate sets of replicates. As a model environmental factor, tobacco smoking appeared 
to explain some of the variation observed in the human samples, even when smoking-associated 
differences in protein concentration were accounted for. The pilot study of tobacco smoke exposure 
provides a proof of principle; despite being underpowered, it demonstrates the possibility of detecting 
significant exposure-related differences in levels of putative adducts. Hence, FS-SRM could also be 
useful for detecting HSA adducts associated with exposures to other environmental factors, providing 
that the adducts are present in relatively high amounts. Knowledge of such associations will be 
valuable for studying human diseases because of the mechanistic relevance of the chemicals from 
which adducts derive. Since FS-SRM does not support detailed structural characterisation, 
16 
 
complementary analytical platforms will be required to fill in the mechanistic details. This endeavour 
will benefit from renewed efforts to enrich HSA adducts. 
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Table 1. Characteristics of participants included in the tobacco smoke study (counts and percentages 
for categorical variables; means and standard deviations for continuous variables). 
Characteristic 
Value 
Never-smokers Smokers 
N 20 20 
Ethnicity 
 European-Caucasian 
 Non-European 
 
20 (100) 
 
 
19 (95) 
1 (5) 
Age (years) 28.15 (5.12)  25.90 (5.30) 
Body-mass index (kg m
−2
) 24.29 (4.78) 24.33 (5.88) 
Education 
 Low 
 Medium  
 High 
 
3 (15) 
6 (30) 
11 (55) 
 
5 (25) 
9 (45) 
6 (30) 
Number of cigarettes per day 0 10 (8.69) 
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Table 2. Technical variation among subsets of Nes
+
 controls at selected SPs. Each value is a 
coefficient of variation, calculated with exclusion of false negatives (no parentheses), or from all 
relevant responses (in parentheses). The estimates of within-batch variation (A and B) come from 
different batches. The values for d_125.1 relate to the data in Fig. 6. 
Type of Variation 
Coefficient of variation for responses at SP 
d_71.1 d_107.1 d_111.6 d_125.1 d_156.6 d_161.1 
Among-batch 0.45 (0.45) 0.49 (0.64) 0.83 (1.10) 0.18 (0.18) 0.53 (0.53) 0.48 (0.48) 
Within-batch (A) 0.68 (0.68) 0.94 (1.21) 0.48 (0.48) 0.38 (0.38) 0.38 (0.38) 0.54 (0.54) 
Within-batch (B) 0.95 (0.95) 0.34 (1.23) 0.26 (0.26) 0.28 (0.28) 0.23 (0.23) 0.61 (0.61) 
TQ-MS only 0.71 (0.71) 0.34 (0.59) 0.31 (0.61) 0.20 (0.20) 0.34 (0.34) 0.61 (0.71) 
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Figure 1. Theoretical basis of FS-SRM (e.g., detection of an N-ethylmaleimide adduct at Cys-34 of 
HSA): (A) Upon collision-induced dissociation (CID) of a triply-protonated T3 peptide, a constant 
fragment (singly-charged b5) is lost and a variable fragment (doubly-charged y16) is detected. A formal 
disconnection (dashed line) distinguishes atoms belonging to the T3 peptide from those contributing 
to the net gain in mass (d); (B) Sampling points (SPs) are values of d at which ion intensities are 
measured. Each SP specifies a pair of m/z values that permit stable ion trajectories in Q1 and Q3, 
respectively. The evenly-spaced points on the plot relate to stable trajectories of [M + 3H]
3+
 ions in 
Q1 and y16 ions in Q3. If “step” and “bin” are of equivalent size, each adduct should be detected once 
and only once. “d_125.1” is the SP at which we would expect to detect the N-ethylmaleimide adduct 
(dadduct = 125 Da). 
 
Figure 2. A workflow for HSA adductomics comprising sample preparation, TQ-MS and data 
processing. Processes are represented by arrows (dashed grey line = initial method; solid black line = 
final method). HSA is extracted from serum or plasma and digested with trypsin. Relevant digestion 
products are purified collectively (one of two possible clean-up methods) and analysed using TQ-MS 
(one of two possible sample delivery methods). The raw data are processed and tabulated in 
preparation for statistical analysis. Protein concentration data from a separate assay, carried out in 
parallel, can feed into the final stages of data processing. 
 
Figure 3. Distributions of putative HSA adducts (mean responses) observed in different plasma 
preparations: (A) human plasma spiked with Nes-HSA; (B) human plasma without Nes-HSA; (C) 
bovine plasma. “L” indicates the estimated detection limit. “d_125.1” is the SP at which detection of 
Nes-HSA was expected. Error bars represent s.d. for at least three technical replicates. Where only 
two replicates were available, the individual data are plotted. 
 
Figure 4. Effect of separation (dSP – danalyte) on the responsiveness of FS-SRM. The results indicate 
that if danalyte is more than half a step (ΔdSP/2 = 2.25 Da) away from dSP, then the analyte will be 
detected at a different SP. This confirms that ΔdSP = 4.5 Da is an appropriate size of step. 
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Figure 5. Effect of varying the amount of Nes-HSA on the response at d_125.1: (A) The relative 
amount of Nes-HSA with respect to total protein was fixed at 1% (w/w) and the amount of total 
protein was varied; (B) the amount of total protein was fixed at 79 µg and the amount of Nes-HSA 
was varied. Linear regression analysis was performed using mean responses as defined by the key 
(full replicate: digestion, clean-up and MS; partial replicate: MS only). The range of amounts of total 
protein derived from ENVIRONAGE subjects’ plasma is indicated in part A. “L” indicates the 
estimated detection limit. 
 
Figure 6. Sources of technical variation inferred from apparent amounts of Nes-HSA in Nes
+
 controls. 
Among-batch variation was inferred from Nes
+
 controls processed at the ends of “subject blocks” 
(i.e., batches of ENVIRONAGE samples). Within-batch variation was inferred from batches 
consisting of solely of Nes
+
 controls. “Either” indicates overlap between sets of technical replicates. 
Periodic replacement of the nano-electrospray emitter (“MS sessions”) was considered as another 
possible source of technical variation (“MS only”). 
 
Figure 7. Distributions of p-values obtained from Wilcoxon rank-sum tests (testing for associations 
between smoking status and responses at SPs). The dashed lines indicate corrected and uncorrected 
significance levels (p = 0.01 and p = 0.05, respectively). The p-values showed a limited dependency 
on the method used to determine smoking status (self-report or cotinine assay). 
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